Rebamipide: New opportunities of gastroenteroprotection


如何引用文章

全文:

详细

This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and locomotor systems. Particular emphasis is laid on the new Russian drug rebamibide that is a stimulant of prostaglandin and glycoprotein synthesis and an inhibitor of the synthesis of oxidative stress products, inflammatory cytokines, and chemokines in the gastrointestinal mucosa. The advantage of rebamipide over classical gastroprotectors is its proven additional effect on the small and large intestinal mucosa. This drug has been registered and is actively used in a number of countries, including Japan, South Korea, and China.

作者简介

V Simanenkov

S Tikhonov

参考

  1. Emery P. Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand J Rheumatol. 1996;25(105):5-12.
  2. Lain L. Approaches to nonsteroidal antiinflammatory drug use in high-risk patient. Gastroenterology. 2001;120:594-606.
  3. Rang H. Pharmacology. 5th ed. Edinburgh: Churchill Livingstone; 2003.
  4. Bruton LL. Goodman and Gilmans. The pharmacological basis of therapeutics. NY: McGrawHill; 2014.
  5. Кукес В.Г. Клиническая фармакология. М.: ГЭОТАР-Медиа; 2009.
  6. Клинические рекомендации по применению НПВП. Под ред. Каратаева А.Е. М.: Има Пресс; 2009.
  7. Derry S, Loke Y. Risk of gastrointestinal haemorrhage with long term use of aspirin: metaanalysis. BMJ. 2002;52:1183-1187.
  8. Biskupiak J, Brixner D, Howard K. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother. 2006;20(3):7-14.
  9. Silverstein F, Faich G, Goldstein J. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: arandomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;284:1247-1255.
  10. Laponte R, Ibanes L, Vidal X. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. DrugSuf. 2004;27:411-420.
  11. Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287-293.
  12. Верткин А.Л., Вовк Е.И., Наумов А.В. Лечение и профилактика поражений слизистой оболочки желудочно-кишечного тракта в терапевтической практике. Клинические перспективы гастроэнтерологии, гепатологии. 2009;1:35-41.
  13. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б., Кукушкин М.Л., Дроздов В.Н., Исаков В.А., Насонов Е.Л. Применение нестероидных противовоспалительных препаратов. М.: Има ПРЕСС; 2009.
  14. Клинические рекомендации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Российская Гастроэнтерологическая Ассоциация. Доступно по http://www.gastro.ru. Ссылка активна на 10.09.2015.
  15. Zhang W, Doherty M, Bardin T. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.
  16. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327(11):749-754.
  17. Graham DY, Opekun AR. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-59.
  18. Fujimori S, Gudis K, Takahashi Y. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Investn. 2010;40(6):504-510. doi: 10.1111/j.1365-2362.2010.02290.x.
  19. Ткач С.М., Балабанцева А.П. Современные подходы к лечению НПВП-энтеропатий. Сучасна Гастроентерология. 2014;6(80):37-42.
  20. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin N Am. 2010;39(3):433-464. doi: 10.1016/j.gtc.2010.08.010.
  21. Goel GA, Deshpande A, Lopez R. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422-427. doi: 10.1016/j.cgh.2011.11.019.
  22. Kim JW. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3571-3577.
  23. Fujimori S, Seo T, Gudis K. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69(7):1339-1346. doi: 10.1016/j.gie.2008.08.017.
  24. Lim YJ, Chun HJ. Recent advances in NSAIDs-induced enteropathy therapeutics: new options, new challenges. Gastroenterol. 2013;4:760-767. doi: 10.1155/2013/761060.
  25. Endo H, Higurashi T, Hosono K. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. JGastroenterol. 2011;46(7): 894-905. doi: 10.1007/s00535-011-0410-1.
  26. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and nsaids as a novel strategy to reduce gastrointestinal toxicity. Drugs Today. 2009;45(12):877-890. doi:1396674/dot.2009.45.12.1441075.
  27. Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13.
  28. Xiong J, Lai S, Zhang P. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93(12):64. doi: 10.1097/md.0000000000000064.
  29. Shin WG, Kim SJ, Choi MH. Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointest Endosc. 2012;75(4):739-747. doi: 10.1016/j.gie.2011.11.004.
  30. Du Y, Li Z, Zhan X. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;11:2886-2895. doi: 10.1007/s10620-007-0180-z.
  31. Terano A, Arakawa T. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690-693.
  32. Park SH, Cho CS, Lee OY. Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. J Clin Biochem Nutr. 2007;40(2):148-155. doi: 10.3164/jcbn.40.148.
  33. Mizukami K, Murakami K. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011;46:5117-5122. doi: 10.3748/wjg.v17.i46.5117.
  34. Zhang S, Qing Q, Bai Y. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;7:1991-2000. doi: 10.1007/s10620-013-2606-0.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2015

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##